Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (6): 1229-1233. doi: 10.19723/j.issn.1671-167X.2022.06.029

Previous Articles     Next Articles

红霞 李1,雅馨 周1,亚飞 王2,鹏宇 王2,振彪 吴2,*()   

  • Received:2022-08-27 Online:2022-12-18 Published:2022-12-19
  • Contact: 振彪 吴 E-mail:wuzhenbiaoxjimmu@163.com
  • Supported by:
    National Key Research Development Program of China(201KTCL03_03)

RICH HTML

 1   

PDF (PC)

90

CLC Number: 

  • R593.2

Figure 1

Different changes of labial salivary glands in pSS patients A, normal pathology; B, lymphocyte infiltration (arrow) but no focus score (FS=0); C, non-specific chronic sialadenitis having lymphocyte infiltration (arrow); D, lymphocytic focuses (FS=6.3, arrow). FS, focus score; pSS, primary Sjögren's syndrome."

Table 1

Comparison of clinical parameters between positive-pSS and negative-pSS patients"

Variables Positive-pSS (n=104) Negative-pSS (n=113) Statistics P
Age/years, $\bar x \pm s$ 48.5±14.9 49.6±14.2 0.440 0.508
Gender (Males/Females), n 5/99 7/106 0.199 0.655
Duration/months, M(P25, P75) 12 (6, 45) 14 (6, 36) 0.802 0.423
Dry mouth 83 (79.8) 83 (73.4) 1.217 0.270
Dry eyes 62 (59.6) 59 (52.2) 1.203 0.273
Parotid swelling 11 (10.6) 15 (13.3) 0.374 0.541
Rampant caries 22 (21.2) 13 (11.5) 3.728 0.054
Arthralgia/Anthritis 16 (15.4) 28 (24.8) 2.957 0.086
Rash 20 (19.2) 22 (19.5) 0.002 0.965
Fever 5 (4.8) 8 (7.1) 0.496 0.481
Hematological involvement 34 (32.7) 34 (30.1) 0.171 0.680
  Leukocytopenia 29 (27.9) 22 (19.5) 2.133 0.144
  Thrombocytopenia 15 (14.4) 15 (13.3) 0.060 0.807
Interstitial pneumonia 10 (9.6) 10 (8.9) 0.038 0.846
Kidney involvement 7 (6.7) 5 (4.4) 0.551 0.458
Nerve involvement 5 (4.8) 9 (8.0) 0.894 0.344
WUSF rate≤0.1 mL/min 46/69 (66.7) 63/80 (78.8) 2.754 0.097
Schirmer test ≤ 5 mm/5 min 43/69 (62.3) 41/77 (53.2) 1.226 0.268
ESSDAI, $\bar x \pm s$ 6.7±5.4 5.7±4.4 3.486 0.063
  ESSDAI＜5 44 (42.3) 51 (45.1) 0.176 0.675
  5≤ESSDAI＜10 31 (29.8) 42 (37.2) 1.314 0.252
  ESSDAI≥10 29 (27.9) 20 (17.7) 3.214 0.073

Table 2

Comparison of immune indicators between positive-pSS and negative-pSS patients [n (%)]"

Variables Positive-pSS (n=104) Negative-pSS (n=113) Statistics P
ANA seropositive 101 (97.1) 111 (98.2) 0.009 0.925
  ANA titer = 1 ∶100 6 (5.8) 14 (12.4) 2.837 0.092
  ANA titer = 1 ∶320 9 (8.7) 20 (17.7) 3.723 0.054
  ANA titer = 1 ∶1 000 19 (18.3) 26 (23.0) 0.740 0.390
  ANA titer ≥ 1 ∶3 200 67 (64.4) 51 (45.1) 8.123 0.004
Anti-SSA 86 (82.7) 98 (86.7) 0.683 0.408
Anti-Ro-52 87 (83.7) 90 (79.6) 0.579 0.447
Anti-SSB 48 (46.2) 34 (30.1) 5.946 0.015
AMA-M2 8 (7.7) 15 (13.3) 1.781 0.182
Anti-CENP-B 8 (7.7) 10 (8.9) 0.095 0.757
Anti-RNP/Sm 11 (10.6) 12 (10.6) 0.000 0.992
Anti-dsDNA 0 1 (0.9)
Anti-CCP 1/40 (2.5) 2/43 (4.7) >0.999
IgG>1 600 mg/dL 71/96 (74.0) 60/99 (60.6) 3.941 0.047
IgA>450 mg/dL 18/96 (18.8) 13/99 (13.1) 1.151 0.283
IgM>270 mg/dL 9/96 (9.4) 7/99 (7.1) 0.344 0.558
C3 < 80 mg/dL 43/96 (44.8) 37/97 (38.1) 0.878 0.349
C4 < 16 mg/dL 36/96 (37.5) 33/97 (34.0) 0.254 0.614
RF seropositive 70/96 (72.9) 56/97 (57.7) 4.909 0.027
ESR>20 mm/h 48/83 (57.8) 31/82 (37.8) 6.629 0.010
CRP>0.8 mg/dL 9/94 (9.6) 5/97 (5.2) 1.373 0.241

Table 3

Analysis of variables associated with positive pathology in pSS patients"

Variables OR (95%CI) P value
Rampant caries 1.608 (0.723-3.576) 0.245
ANA titer ≥ 1 ∶3 200 1.592 (0.838-3.025) 0.155
Anti-SSB positive 1.190 (0.616-2.299) 0.604
ESR>20 mm/h 2.239 (0.657-2.337) 0.508
IgG>1 600 mg/dL 1.635 (0.813-3.290) 0.168
RF seropositive 0.875 (0.448-1.710) 0.696
ESSDAI
  ESSDAI < 5 Reference
  5≤ESSDAI < 10 0.711 (0.357-1.419) 0.334
  ESSDAI≥10 1.554 (0.723-3.340) 0.259
1 张文, 厉小梅, 徐东, 等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志, 2020, 59 (4): 269- 270.
doi: 10.3760/cma.j.cn112138-20200113-00021
2 Mariette X , Criswell LA . Primary Sjögren' s syndrome[J]. N Engl J Med, 2018, 378 (10): 931- 939.
doi: 10.1056/NEJMcp1702514
3 Shiboski CH , Shiboski SC , Seror R , et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren' s syndrome: A consensus and data-driven methodology involving three international patient cohorts[J]. Ann Rheum Dis, 2017, 76 (1): 9- 16.
doi: 10.1136/annrheumdis-2016-210571
4 Seror R , Ravaud P , Bowman SJ , et al. EULAR Sjögren' s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2010, 69 (6): 1103- 1109.
doi: 10.1136/ard.2009.110619
5 Vitali C , Bombardieri S , Jonsson R , et al. Classification criteria for Sjögren' s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis, 2002, 61 (6): 554- 558.
doi: 10.1136/ard.61.6.554
6 Guellec D , Cornec D , Jousse-Joulin S , et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren' s syndrome: A systematic review[J]. Autoimmun Rev, 2013, 12 (3): 416- 420.
doi: 10.1016/j.autrev.2012.08.001
7 Fisher BA , Jonsson R , Daniels T , et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2017, 76 (7): 1161- 1168.
doi: 10.1136/annrheumdis-2016-210448
8 Retamozo S , Acar-Denizli N , Rasmussen A , et al. Systemic manifestations of primary Sjögren' s syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients[J]. Clin Exp Rheumatol, 2019, 37 (3/Suppl 118): 97- 106.
9 Luppi F , Sebastiani M , Silva M , et al. Interstitial lung disease in Sjögren' s syndrome: A clinical review[J]. Clin Exp Rheumatol, 2020, 38 (4/Suppl 126): 291- 300.
10 Lin W , Xin Z , Ning X , et al. Clinical features and risk factors of Raynaud' s phenomenon in primary Sjögren' s syndrome[J]. Clin Rheumatol, 2021, 40 (10): 4081- 4087.
doi: 10.1007/s10067-021-05749-w
11 Sharma R , Chaudhari KS , Kurien BT , et al. Sjögren syndrome without focal lymphocytic infiltration of the salivary glands[J]. J Rheumatol, 2020, 47 (3): 394- 399.
doi: 10.3899/jrheum.181443
12 Park Y , Lee J , Koh JH , et al. Positive histopathologic assessment in salivary glands shows little impact on clinical features of established primary Sjögren' s syndrome in a Korean population[J]. Clin Exp Rheumatol, 2020, 38 (4/ Suppl 126):): 158- 165.
13 Risselada AP , Kruize AA , Goldschmeding R , et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2014, 73 (8): 1537- 1540.
doi: 10.1136/annrheumdis-2013-204634
14 Kakugawa T , Sakamoto N , Ishimoto H , et al. Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren' s syndrome[J]. Respir Med, 2018, 137, 95- 102.
doi: 10.1016/j.rmed.2018.02.023
15 Wu S , Tang X , Wu L , et al. Anti-Ro52 antibodies in clinical practice: A single-centre experience[J]. Int J Clin Pract, 2021, 75 (3): e13679.
[1] Fang CHENG,Shao-ying YANG,Xing-xing FANG,Xuan WANG,Fu-tao ZHAO. Role of the CCL28-CCR10 pathway in monocyte migration in rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1074-1078.
[2] Jing-feng ZHANG,Yin-ji JIN,Hui WEI,Zhong-qiang YAO,Jin-xia ZHAO. Cross-sectional study on quality of life and disease activity of rheumatoid arthritis patients [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1086-1093.
[3] Lu ZHANG,Cheng CHEN,Mei-ting WENG,Ai-ping ZHENG,Mei-ling SU,Qing-wen WANG,Yue-ming CAI. Characteristics of serum autoantibodies in patients with lupus nephritis and tubulointerstitial damage [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1094-1098.
[4] Lin-qi ZHANG,Jing ZHAO,Hong-yan WANG,Zong-yi WANG,Ying-ni LI,Ji-yang TANG,Si-ying LI,Jin-feng QU,Ming-wei ZHAO. Relationship between anti-ENO1 antibody and systemic lupus erythematosus patients with retinopathy [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1099-1105.
[5] Miao SHAO,Hui-fang GUO,Ling-yan LEI,Qing ZHAO,Yan-jie DING,Jin LIN,Rui WU,Feng YU,Yu-cui LI,Hua-li MIAO,Li-yun ZHANG,Yan DU,Rui-ying JIAO,Li-xia PANG,Li LONG,Zhan-guo LI,Ru LI. A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1112-1116.
[6] Yang LIU,Fang CHENG,Yan-ling WANG,Xiang-yan AI,Zhen-hang ZHU,Fu-tao ZHAO. Diagnostic performances of salivary gland ultrasonography for Sjögren's syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1123-1127.
[7] Rui-jie CAO,Zhong-qiang YAO,Peng-qing JIAO,Li-gang CUI. Comparison of diagnostic efficacy of different classification criteria for Takayasu arteritis in Chinese patients [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1128-1133.
[8] Xiao-yan XING,Jun-xiao ZHANG,Feng-yun-zhi ZHU,Yi-fan WANG,Xin-yao ZHOU,Yu-hui LI. Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1214-1218.
[9] 靓 罗,青猛 蔡,香君 刘,泽霖 贠,春 李,晓盈 张. [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1224-1228.
[10] 适 陈,田 刘. [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1065-1067.
[11] Wen-xin CAI,Shi-cheng LI,Yi-ming LIU,Ru-yu LIANG,Jing LI,Jian-ping GUO,Fan-lei HU,Xiao-lin SUN,Chun LI,Xu LIU,Hua YE,Li-zong DENG,Ru LI,Zhan-guo LI. A cross-sectional study on the clinical phenotypes of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1068-1073.
[12] Rui LIU,Jin-xia ZHAO,Liang YAN. Clinical characteristics of patients with rheumatoid arthritis complicated with venous thrombosis of lower extremities [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1079-1085.
[13] Min LI,Lin-qing HOU,Yue-bo JIN,Jing HE. Clinical and immunological characteristics of systemic lupus erythematosus with retinopathy [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1106-1111.
[14] Yu-ke HOU,Qing-meng CAI,Xiang-jun LIU,Ze-lin YUN,Chun LI,Xue-wu ZHANG. Clinical significance of oxidized low-density lipoprotein antibody in antiphospholipid syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1117-1122.
[15] 朝焰 徐,长艺 林,达梅 叶,培埕 吴,明辉 宋,有添 刘,琼 邓,雪艳 黄,忠晓 范,雪兰 游. [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1234-1237.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[2] . [J]. Journal of Peking University(Health Sciences), 2001, 33(2): 181 -182 .
[3] . [J]. Journal of Peking University(Health Sciences), 2007, 39(6): 663 -665 .
[4] . [J]. Journal of Peking University(Health Sciences), 2008, 40(1): 39 -42 .
[5] . [J]. Journal of Peking University(Health Sciences), 2010, 42(6): 739 -745 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(5): 507 -510 .
[7] . [J]. Journal of Peking University(Health Sciences), 2000, 32(4): 300 .
[8] . [J]. Journal of Peking University(Health Sciences), 2008, 40(2): 146 -150 .
[9] . [J]. Journal of Peking University(Health Sciences), 2008, 40(4): 369 -373 .
[10] . [J]. Journal of Peking University(Health Sciences), 2010, 42(2): 126 -130 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd